NEFL and kidney disorder: FST-treated Leprdb/db simultaneously ameliorated retinopathy and nephropathy by increasing the thickness of NFL and GCL + IPL (4.87 ± 1.79 μm for NFL and 54.21 ± 5.14 μm for GCL + IPL, respectively) and diminishing the glomerular area (∼42%) (Figures 5C,D).